Inflammatory neuropathies: How far we’ve come
Article Sidebar
Published
Mar 6, 2024
Downloads
Download data is not yet available.
Submit your own article
Register as an author to reserve your spot in the next issue of the Medical Research Archives.
Author RegistrationJoin the Society
The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.
Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.
MembershipMain Article Content
Kradolfer Letts Nicole Brigitte
http://orcid.org/0000-0002-2109-0573
Bertorini Tulio
http://orcid.org/0000-0002-0028-5929
http://orcid.org/0000-0002-2109-0573
Bertorini Tulio
http://orcid.org/0000-0002-0028-5929
Abstract
Inflammatory polyneuropathies encompass a range of common and treatable conditions arising from an immune response—either humoral or cellular—targeting specific elements of the peripheral nervous system. These conditions may be acute, as in Guillain-Barré syndrome and its variants, or chronic, as observed in chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, POEMS, vasculitis neuropathies, or nodal-paranodal disorders. Diagnosis predominantly hinges on clinical symptoms and electromyographic examinations, facilitating the prompt commencement of treatment. Addressing less common pathologies is crucial when conventional treatments prove ineffective, emphasizing the need for ongoing research in this dynamic field.
Keywords:
Inflammatory neuropathies, neuropathies
Article Details
How to Cite
BRIGITTE, Kradolfer Letts Nicole; TULIO, Bertorini.
Inflammatory neuropathies: How far we’ve come.
Medical Research Archives, [S.l.], v. 12, n. 2, mar. 2024.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/4563>. Date accessed: 27 apr. 2024.
doi: https://doi.org/10.18103/mra.v12i2.4563.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire. Remarques sur les car- actères cliniques et graphiques des réflexes tendineux. Bull Mém Soc Méd Hôp Paris 1916; 40: 1462-70.
2. FISHER M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57-65. doi:10.1056/ NEJM195607122550201
3. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123 -133. doi:10.1159/000324710
4. Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866-2877. doi:10.1093/brain/awy232
5. Bertorini T. Neuromuscular disorders, treatment and diagnosis. Second edition. Elsevier. 2022.
6. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10 280):1214-1228. doi:10.1016/S0140-6736(21)00517-1
7. Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry. 2013;84(5):576-583. doi:10.1136/ jnnp-2012-302824
8. Moscona-Nissan A Sr, López-Hernández JC, Seidman-Sorsby A, Cruz-Zermeño M, Navalón-Calzada A. Pharyngeal-Cervical-Brachial Variant of Guillain-Barré Syndrome. Cureus. 2021;13(10):e18788. Published 2021 Oct 14. doi:10.7759/cureus.18788
9. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683. doi:10.1038/s4 1582-019-0250-9
10. Luijten LWG, Leonhard SE, van der Eijk AA, et al. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain. 2021;144 (11):3392-3404. doi:10.1093/brain/awab279
11. Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021;144(2):682-693. doi:10.1093/brain/awaa433
12. Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Hum Vaccin Immunother. 2018;14(11):2568-2579. doi:10.1080/21645515.2018.1493415
13. Ashbury AK, Arnason BGW, Karp HR, et al. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978;3(6):565-566. doi:10.1002/ana.410030628
14. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3) :599-612. doi:10.1016/j.vaccine.2010.06.003
15. Arends S, Drenthen J, van den Bergh P, et al. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clin Neurophysiol. 2022;138:231-240. doi:10.1016/j.clinph.2021.12.014
16. Freiha J, Zoghaib R, Makhoul K, et al. The value of sensory nerve conduction studies in the diagnosis of Guillain-Barré syndrome. Clin Neurophysiol. 2021;132(5):1157-1162. doi: 10.1016/j.clinph.2021.02.013
17. Rasera A, Romito S, Segatti A, et al. Very early and early neurophysiological abnormalities in Guillain-Barré syndrome: A 4-year retrospective study. Eur J Neurol. 2021;28 (11):3768-3773. doi:10.1111/ene.15011
18. Illes Z, Blaabjerg M. Cerebrospinal fluid findings in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathies. Handb Clin Neurol. 2017;146: 125-138. doi:10.1016/B978-0-12-804279-3.00009-5
19. Al-Hakem H, Doets AY, Stino AM, et al. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. Neurology. 2023; 100(23):e2386-e2397. doi: 10.1212/WNL.0000000000207282
20. Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2017;88 (4):346-352. doi:10.1136/jnnp-2016-314862
21. Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(4):275-283. doi:10.1016/S14 74-4422(20)30494-4
22. Lin J, Gao Q, Xiao K, Tian D, Hu W, Han Z. Efficacy of therapies in the treatment of Guillain-Barre syndrome: A network meta-analysis. Medicine (Baltimore). 2021;100(41):e 27351. doi:10.1097/MD.0000000000027351
23. Verboon C, van den Berg B, Cornblath DR, et al. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. J Neurol Neurosurg Psychiatry. 2020;91(2):113-121. doi:10.1136/jnnp-2019-321496
24. Verboon C, Harbo T, Cornblath DR, et al. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. J Neurol Neurosurg Psychiatry. 2021;92(10):1080-1088. doi:10.11 36/jnnp-2020-325815
25. Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;10(10):CD001446. Published 2016 Oct 24. doi:10.1002/14651858.CD001446.pub5
26. Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17 (6):519-529. doi:10.1016/S1474-442 2(18)30114-5
27. Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2020;1 (1):CD008630. Published 2020 Jan 25. doi: 10.1002/14651858.CD008630.pub5
28. Doets AY, Lingsma HF, Walgaard C, et al. Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score. Neurology. 2022;98(5):e518-e532. doi:10.121 2/WNL.0000000000013139
29. Doets AY, Walgaard C, Lingsma HF, et al. International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score. Ann Neurol. 2022;91 (4):521-531. doi:10.1002/ana.26312
30. Ren K, Yang A, Lu J, et al. Association between serum low-density neutrophils and acute-onset and recurrent Guillain-Barré syndrome. Brain Behav. 2022;12(1):e2456. doi:10.1002/brb3.2456
31. Broers MC, de Wilde M, Lingsma HF, van der Lei J, Verhamme KMC, Jacobs BC. Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands. J Peripher Nerv Syst. 2022;27(3):182-188. doi:10.1111/jns.12502
32. Querol LA, Hartung HP, Lewis RA, et al. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics. 2022; 19(3):864-873. doi: 10.1007/s13311-022-01221-y
33. Tang L, Huang Q, Qin Z, Tang X. Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features. J Neurol. 2021;268(8):2757-2768. doi:10.1007/ s00415-020-09823-2
34. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2022;27(1):94. doi:10.1111/jns.12479
35. Stino AM, Naddaf E, Dyck PJ, Dyck PJB. Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach. Muscle Nerve. 2021;63(2):157-169. doi:10.1002/mus.27046
36. Herraets IJT, Goedee HS, Telleman JA, et al. Nerve ultrasound for diagnosing chronic inflammatory neuropathy: A multicenter validation study. Neurology. 2020;95(12):e17 45-e1753. doi:10.1212/WNL.0000000000010369
37. Pitarokoili K, Sturm D, Labedi A, et al. Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord. 2019;12: 1756286419855485. Published 2019 Jun 18. doi:10.1177/1756286 419855485
38. Su X, Kong X, Kong X, Zhu Q, Lu Z, Zheng C. Multisequence magnetic resonance neurography of brachial and lumbosacral plexus in chronic inflammatory demyelinating polyneuropathy: correlations with electrophysiological parameters and clinical features. Ther Adv Neurol Disord. 2023;16: 17562864221150540. Published 2023 Feb 6. doi:10.1177/17562864221150540
39. Eftimov F, Lucke IM, Querol LA, Rajabally YA, Verhamme C. Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2020;143 (11):3214-3224. doi:10.1093/brain/awaa265
40. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol. 2013;124(10):1928-1934. doi: 10.1016/j.clinph.2013.03.025
41. Kira JI. Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism. Front Neurol. 2021;12:665136. Published 2021 Jun 10. doi: 10.3389/fneur.2021.665136
42. Delmont E, Manso C, Querol L, et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain. 2017;140(7):1851-1858. doi:10.1093/brain/awx124
43. Cortese A, Lombardi R, Briani C, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2019;7(1):e63 9. Published 2019 Nov 21. doi:10.1212/NXI. 0000000000000639
44. Liu B, Zhou L, Sun C, et al. Clinical profile of autoimmune nodopathy with anti-neurofascin 186 antibody. Ann Clin Transl Neurol. 2023;10 (6):944-952. doi:10.1002/ acn3.51775
45. Pascual-Goñi E, Fehmi J, Lleixà C, et al. Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2021;144 (4):1183-1196. doi:10.1093/brain/awab014
46. Martín-Aguilar L, Lleixà C, Pascual-Goñi E, et al. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy [published correction appears in Neurol Neuroimmunol Neuroinflamm. 2021 Dec 20;9 (1):]. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1098. Published 2021 Nov 2. doi:10.1212/NXI.0000000000001098
47. Kumar A, Patwa HS, Nowak RJ. Immunoglobulin therapy in the treatment of multifocal motor neuropathy. J Neurol Sci. 2017;375:190-197. doi:10.1016/j.jns.2017.01.061
48. Yeh WZ, Dyck PJ, van den Berg LH, Kiernan MC, Taylor BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry. 2020;91(2):140-148. doi:10.1136/jnnp-2019-321532
49. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst. 2010;15(4): 295-301. doi:10.1111/j.1529-8027.2010.00290.x
50. Steck AJ. Anti-MAG neuropathy: From biology to clinical management. J Neuroimmunol. 2021;361:577725. doi:10.10 16/j.jneuroim.2021.577725
51. Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord. 2018 Jan 15;11:1756 285617746640. doi: 10.1177/175628561774 6640. PMID: 29403542; PMCID: PMC5791554.
52. Dispenzieri A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96(7):872-888. doi:10.1002/ajh.26240
53. Dispenzieri A. POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(7):812-827. doi:10.1002/ajh.25495
54. Khouri J, Nakashima M, Wong S. Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review. JAMA Oncol. 2021;7(9):1383-1391. doi:10.10 01/jamaoncol.2021.0586
55. Pihan M, Keddie S, D'Sa S, et al. Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e48 6. Published 2018 Aug 15. doi:10.1212/NXI. 0000000000000486
56. Tomasso A, Innocenti I, Autore F, et al. VEGF and IL-6 Correlation in POEMS: a Potential Upcoming Marker of Active Disease and Early Autologous BMT Response. Mediterr J Hematol Infect Dis. 2022;14 (1):e2022007. Published 2022 Jan 1. doi:10. 4084/MJHID.2022.007
57. Collins MP, Dyck PJ, Gronseth GS, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15(3):176-184. doi: 10.1111/j.1529-8027.2010.00281.x
58. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603-606. doi:10. 1007/s10157-013-0869-6
59. Beachy N, Satkowiak K, Gwathmey KG. Vasculitic Neuropathies. Semin Neurol. 2019 ;39(5):608-619. doi:10.1055/s-0039-1688990
60. Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. 2003;61(5): 623-630. doi:10.1212/01.wnl.0000082715.48844.3e
61. Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol. 2017; 13(5):302-316. doi:10.1038/nrneurol.2017.42
62. Van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245-253. doi:10.101 6/S1474-4422(10)70021-1
63. Pegat A, Boisseau W, Maisonobe T, et al. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment. J Peripher Nerv Syst. 2020;25(2):162-170. doi:10.1111/jns.12380
64. Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2019;90(2):125-132. doi:10.1136/jnnp-2018-318714
65. Cornblath DR, van Doorn PA, Hartung HP, et al. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022;1 45(3):887-896. doi:10.1093/brain/awab422
66. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial [published correction appears in Lancet Neurol. 2008 Sep;7(9):771]. Lancet Neurol. 2008;7(2):136-144. doi:10.1016/S1474-4422( 07)70329-0
67. Van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Neurol. 2018 Jan;17 (1):26] [published correction appears in Lancet Neurol. 2018 Aug;17(8):661]. Lancet Neurol. 2018;17(1):35-46. doi:10.1016/S1474-4422(1 7)30378-2
68. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Cavaletti G, Giannini F, Sabatelli M, Beghi E; IMC Trial Group. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):729-34. doi: 10.1136/jnnp-2013-307515. Epub 2014 Sep 22. PMID: 25246645.
69. Adrichem ME, Bus SR, Wieske L, Mohammed H, Verhamme C, Hadden R, van Schaik IN, Eftimov F. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. Eur J Neurol. 2020 Mar;27(3):506-513. doi: 10.1111 /ene.14096. Epub 2019 Nov 7. PMID: 3157 1349; PMCID: PMC7028131.
70. Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;2015(8):C D003906. Published 2015 Aug 25. doi:10.10 02/14651858.CD003906.pub4
71. Hughes R, Dalakas MC, Merkies I, et al. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial [published correction appears in Lancet Neurol. 2018 Nov;17(11):933]. Lancet Neurol. 2018;17 (8):689-698. doi:10.1016/S1474-4422(18)30202-3
72. Querol L, Lleixà C. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP. Neurotherapeutics. 2021;18(4):2222-2235. doi:10.1007/s13311-021-01117-3
73. Jentzer A, Attal A, Roué C, et al. IgG4 Valency Modulates the Pathogenicity of Anti-Neurofascin-155 IgG4 in Autoimmune Nodopathy. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e200014. Published 2022 Aug 10. doi:10.1212/NXI.00000000002 00014
74. Hänggi P, Aliu B, Martin K, Herrendorff R, Steck AJ. Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e11 09. Published 2021 Nov 10. doi:10.1212/NXI. 0000000000001109
75. Keddie S, Eftimov F, van den Berg LH, Brassington R, de Haan RJ, van Schaik IN. Immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2022 Jan 11;1(1):CD004429. doi: 10.1002/ 14651858.CD004429.pub3. PMID: 35015296; PMCID: PMC8751207.
76. Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 1997;63(6):765-769. doi:10.1136/jnnp.63.6.765
77. Sekiguchi Y, Misawa S, Shibuya K, et al. Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol Neurosurg Psychiatry. 2013;84 (12):1346-1348. doi:10.1136/jnnp-2012-304874iasu84
2. FISHER M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57-65. doi:10.1056/ NEJM195607122550201
3. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123 -133. doi:10.1159/000324710
4. Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866-2877. doi:10.1093/brain/awy232
5. Bertorini T. Neuromuscular disorders, treatment and diagnosis. Second edition. Elsevier. 2022.
6. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10 280):1214-1228. doi:10.1016/S0140-6736(21)00517-1
7. Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry. 2013;84(5):576-583. doi:10.1136/ jnnp-2012-302824
8. Moscona-Nissan A Sr, López-Hernández JC, Seidman-Sorsby A, Cruz-Zermeño M, Navalón-Calzada A. Pharyngeal-Cervical-Brachial Variant of Guillain-Barré Syndrome. Cureus. 2021;13(10):e18788. Published 2021 Oct 14. doi:10.7759/cureus.18788
9. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683. doi:10.1038/s4 1582-019-0250-9
10. Luijten LWG, Leonhard SE, van der Eijk AA, et al. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain. 2021;144 (11):3392-3404. doi:10.1093/brain/awab279
11. Keddie S, Pakpoor J, Mousele C, et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021;144(2):682-693. doi:10.1093/brain/awaa433
12. Liu S, Dong C, Ubogu EE. Immunotherapy of Guillain-Barré syndrome. Hum Vaccin Immunother. 2018;14(11):2568-2579. doi:10.1080/21645515.2018.1493415
13. Ashbury AK, Arnason BGW, Karp HR, et al. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978;3(6):565-566. doi:10.1002/ana.410030628
14. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3) :599-612. doi:10.1016/j.vaccine.2010.06.003
15. Arends S, Drenthen J, van den Bergh P, et al. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clin Neurophysiol. 2022;138:231-240. doi:10.1016/j.clinph.2021.12.014
16. Freiha J, Zoghaib R, Makhoul K, et al. The value of sensory nerve conduction studies in the diagnosis of Guillain-Barré syndrome. Clin Neurophysiol. 2021;132(5):1157-1162. doi: 10.1016/j.clinph.2021.02.013
17. Rasera A, Romito S, Segatti A, et al. Very early and early neurophysiological abnormalities in Guillain-Barré syndrome: A 4-year retrospective study. Eur J Neurol. 2021;28 (11):3768-3773. doi:10.1111/ene.15011
18. Illes Z, Blaabjerg M. Cerebrospinal fluid findings in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathies. Handb Clin Neurol. 2017;146: 125-138. doi:10.1016/B978-0-12-804279-3.00009-5
19. Al-Hakem H, Doets AY, Stino AM, et al. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. Neurology. 2023; 100(23):e2386-e2397. doi: 10.1212/WNL.0000000000207282
20. Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2017;88 (4):346-352. doi:10.1136/jnnp-2016-314862
21. Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(4):275-283. doi:10.1016/S14 74-4422(20)30494-4
22. Lin J, Gao Q, Xiao K, Tian D, Hu W, Han Z. Efficacy of therapies in the treatment of Guillain-Barre syndrome: A network meta-analysis. Medicine (Baltimore). 2021;100(41):e 27351. doi:10.1097/MD.0000000000027351
23. Verboon C, van den Berg B, Cornblath DR, et al. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. J Neurol Neurosurg Psychiatry. 2020;91(2):113-121. doi:10.1136/jnnp-2019-321496
24. Verboon C, Harbo T, Cornblath DR, et al. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. J Neurol Neurosurg Psychiatry. 2021;92(10):1080-1088. doi:10.11 36/jnnp-2020-325815
25. Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;10(10):CD001446. Published 2016 Oct 24. doi:10.1002/14651858.CD001446.pub5
26. Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17 (6):519-529. doi:10.1016/S1474-442 2(18)30114-5
27. Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2020;1 (1):CD008630. Published 2020 Jan 25. doi: 10.1002/14651858.CD008630.pub5
28. Doets AY, Lingsma HF, Walgaard C, et al. Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score. Neurology. 2022;98(5):e518-e532. doi:10.121 2/WNL.0000000000013139
29. Doets AY, Walgaard C, Lingsma HF, et al. International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score. Ann Neurol. 2022;91 (4):521-531. doi:10.1002/ana.26312
30. Ren K, Yang A, Lu J, et al. Association between serum low-density neutrophils and acute-onset and recurrent Guillain-Barré syndrome. Brain Behav. 2022;12(1):e2456. doi:10.1002/brb3.2456
31. Broers MC, de Wilde M, Lingsma HF, van der Lei J, Verhamme KMC, Jacobs BC. Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands. J Peripher Nerv Syst. 2022;27(3):182-188. doi:10.1111/jns.12502
32. Querol LA, Hartung HP, Lewis RA, et al. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics. 2022; 19(3):864-873. doi: 10.1007/s13311-022-01221-y
33. Tang L, Huang Q, Qin Z, Tang X. Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features. J Neurol. 2021;268(8):2757-2768. doi:10.1007/ s00415-020-09823-2
34. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2022;27(1):94. doi:10.1111/jns.12479
35. Stino AM, Naddaf E, Dyck PJ, Dyck PJB. Chronic inflammatory demyelinating polyradiculoneuropathy-Diagnostic pitfalls and treatment approach. Muscle Nerve. 2021;63(2):157-169. doi:10.1002/mus.27046
36. Herraets IJT, Goedee HS, Telleman JA, et al. Nerve ultrasound for diagnosing chronic inflammatory neuropathy: A multicenter validation study. Neurology. 2020;95(12):e17 45-e1753. doi:10.1212/WNL.0000000000010369
37. Pitarokoili K, Sturm D, Labedi A, et al. Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord. 2019;12: 1756286419855485. Published 2019 Jun 18. doi:10.1177/1756286 419855485
38. Su X, Kong X, Kong X, Zhu Q, Lu Z, Zheng C. Multisequence magnetic resonance neurography of brachial and lumbosacral plexus in chronic inflammatory demyelinating polyneuropathy: correlations with electrophysiological parameters and clinical features. Ther Adv Neurol Disord. 2023;16: 17562864221150540. Published 2023 Feb 6. doi:10.1177/17562864221150540
39. Eftimov F, Lucke IM, Querol LA, Rajabally YA, Verhamme C. Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2020;143 (11):3214-3224. doi:10.1093/brain/awaa265
40. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol. 2013;124(10):1928-1934. doi: 10.1016/j.clinph.2013.03.025
41. Kira JI. Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism. Front Neurol. 2021;12:665136. Published 2021 Jun 10. doi: 10.3389/fneur.2021.665136
42. Delmont E, Manso C, Querol L, et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain. 2017;140(7):1851-1858. doi:10.1093/brain/awx124
43. Cortese A, Lombardi R, Briani C, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2019;7(1):e63 9. Published 2019 Nov 21. doi:10.1212/NXI. 0000000000000639
44. Liu B, Zhou L, Sun C, et al. Clinical profile of autoimmune nodopathy with anti-neurofascin 186 antibody. Ann Clin Transl Neurol. 2023;10 (6):944-952. doi:10.1002/ acn3.51775
45. Pascual-Goñi E, Fehmi J, Lleixà C, et al. Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2021;144 (4):1183-1196. doi:10.1093/brain/awab014
46. Martín-Aguilar L, Lleixà C, Pascual-Goñi E, et al. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy [published correction appears in Neurol Neuroimmunol Neuroinflamm. 2021 Dec 20;9 (1):]. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1098. Published 2021 Nov 2. doi:10.1212/NXI.0000000000001098
47. Kumar A, Patwa HS, Nowak RJ. Immunoglobulin therapy in the treatment of multifocal motor neuropathy. J Neurol Sci. 2017;375:190-197. doi:10.1016/j.jns.2017.01.061
48. Yeh WZ, Dyck PJ, van den Berg LH, Kiernan MC, Taylor BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry. 2020;91(2):140-148. doi:10.1136/jnnp-2019-321532
49. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. J Peripher Nerv Syst. 2010;15(4): 295-301. doi:10.1111/j.1529-8027.2010.00290.x
50. Steck AJ. Anti-MAG neuropathy: From biology to clinical management. J Neuroimmunol. 2021;361:577725. doi:10.10 16/j.jneuroim.2021.577725
51. Dalakas MC. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord. 2018 Jan 15;11:1756 285617746640. doi: 10.1177/175628561774 6640. PMID: 29403542; PMCID: PMC5791554.
52. Dispenzieri A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2021;96(7):872-888. doi:10.1002/ajh.26240
53. Dispenzieri A. POEMS Syndrome: 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(7):812-827. doi:10.1002/ajh.25495
54. Khouri J, Nakashima M, Wong S. Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review. JAMA Oncol. 2021;7(9):1383-1391. doi:10.10 01/jamaoncol.2021.0586
55. Pihan M, Keddie S, D'Sa S, et al. Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome. Neurol Neuroimmunol Neuroinflamm. 2018;5(5):e48 6. Published 2018 Aug 15. doi:10.1212/NXI. 0000000000000486
56. Tomasso A, Innocenti I, Autore F, et al. VEGF and IL-6 Correlation in POEMS: a Potential Upcoming Marker of Active Disease and Early Autologous BMT Response. Mediterr J Hematol Infect Dis. 2022;14 (1):e2022007. Published 2022 Jan 1. doi:10. 4084/MJHID.2022.007
57. Collins MP, Dyck PJ, Gronseth GS, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst. 2010;15(3):176-184. doi: 10.1111/j.1529-8027.2010.00281.x
58. Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603-606. doi:10. 1007/s10157-013-0869-6
59. Beachy N, Satkowiak K, Gwathmey KG. Vasculitic Neuropathies. Semin Neurol. 2019 ;39(5):608-619. doi:10.1055/s-0039-1688990
60. Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. 2003;61(5): 623-630. doi:10.1212/01.wnl.0000082715.48844.3e
61. Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol. 2017; 13(5):302-316. doi:10.1038/nrneurol.2017.42
62. Van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(3):245-253. doi:10.101 6/S1474-4422(10)70021-1
63. Pegat A, Boisseau W, Maisonobe T, et al. Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment. J Peripher Nerv Syst. 2020;25(2):162-170. doi:10.1111/jns.12380
64. Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2019;90(2):125-132. doi:10.1136/jnnp-2018-318714
65. Cornblath DR, van Doorn PA, Hartung HP, et al. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022;1 45(3):887-896. doi:10.1093/brain/awab422
66. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial [published correction appears in Lancet Neurol. 2008 Sep;7(9):771]. Lancet Neurol. 2008;7(2):136-144. doi:10.1016/S1474-4422( 07)70329-0
67. Van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Neurol. 2018 Jan;17 (1):26] [published correction appears in Lancet Neurol. 2018 Aug;17(8):661]. Lancet Neurol. 2018;17(1):35-46. doi:10.1016/S1474-4422(1 7)30378-2
68. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Messina P, Antonini G, Fazio R, Gallia F, Schenone A, Francia A, Pareyson D, Santoro L, Tamburin S, Cavaletti G, Giannini F, Sabatelli M, Beghi E; IMC Trial Group. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):729-34. doi: 10.1136/jnnp-2013-307515. Epub 2014 Sep 22. PMID: 25246645.
69. Adrichem ME, Bus SR, Wieske L, Mohammed H, Verhamme C, Hadden R, van Schaik IN, Eftimov F. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. Eur J Neurol. 2020 Mar;27(3):506-513. doi: 10.1111 /ene.14096. Epub 2019 Nov 7. PMID: 3157 1349; PMCID: PMC7028131.
70. Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;2015(8):C D003906. Published 2015 Aug 25. doi:10.10 02/14651858.CD003906.pub4
71. Hughes R, Dalakas MC, Merkies I, et al. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial [published correction appears in Lancet Neurol. 2018 Nov;17(11):933]. Lancet Neurol. 2018;17 (8):689-698. doi:10.1016/S1474-4422(18)30202-3
72. Querol L, Lleixà C. Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP. Neurotherapeutics. 2021;18(4):2222-2235. doi:10.1007/s13311-021-01117-3
73. Jentzer A, Attal A, Roué C, et al. IgG4 Valency Modulates the Pathogenicity of Anti-Neurofascin-155 IgG4 in Autoimmune Nodopathy. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e200014. Published 2022 Aug 10. doi:10.1212/NXI.00000000002 00014
74. Hänggi P, Aliu B, Martin K, Herrendorff R, Steck AJ. Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e11 09. Published 2021 Nov 10. doi:10.1212/NXI. 0000000000001109
75. Keddie S, Eftimov F, van den Berg LH, Brassington R, de Haan RJ, van Schaik IN. Immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev. 2022 Jan 11;1(1):CD004429. doi: 10.1002/ 14651858.CD004429.pub3. PMID: 35015296; PMCID: PMC8751207.
76. Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 1997;63(6):765-769. doi:10.1136/jnnp.63.6.765
77. Sekiguchi Y, Misawa S, Shibuya K, et al. Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol Neurosurg Psychiatry. 2013;84 (12):1346-1348. doi:10.1136/jnnp-2012-304874iasu84